Dear Colleague,

The Biomarker Summit 2016, to be held on March 21-23, 2016 in San Diego, CA at the Westin San Diego Hotel, is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.

A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.

Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in three major therapeutic areas, formally organized in the following tracks:

General Session:
I. Plenary Keynote Session
II. Big Data Analytics for Biomarker Development
III. Novel Technologies in Biomarker Development
IV. Panel Discussion: Companion Diagnostics Development & Partnering Strategies
V. Panel Discussion: Non-profits & Patient Perspectives on Precision Medicine
VI. Overcoming Challenges of Clinical Validation & Translation
VII. Panel Discussion: Regulatory & Reimbursement Trends in Biomarker Development

9th Oncology Biomarkers
I. Minimally Invasive & Non-invasive Approaches in Cancer
- Liquid Biopsy
- Imaging
II. Emerging Discovery Pipelines
III. Immuno-Oncology Biomarker Discovery

5th Neurological Biomarkers
I. Imaging Approaches in CNS Drug Discovery & Development
II. CSF & Blood Based Biomarker Approaches
III. Developments in Neurological & Neurodegenerative Disorders
IV. Biomarker Development in Neuropsychiatric Disorders

5th Inflammatory & Immunological Biomarkers
I. Biomarkers of Early Progressive Inflammatory & Immunological Diseases
II. Biomarkers & Surrogate Endpoints for Clinical Trials in Inflammatory Diseases
III. Novel Approaches to Immunological Biomarkers
IV. Microbiomes in Immune Modulation & Inflammatory Diseases


Please join us for the opportunity to listen to recent updates on research, share ideas with colleagues, and network with experts to advance biomarker discovery and development.


Best regards,

2016 Advisory Committee